Navidea Biopharmaceuticals CEO Jed Latkin's 2020 pay jumps 66% to $1.2M

Navidea Biopharmaceuticals reports 2020 executive compensation

By ExecPay News

Published: August 2, 2021

Navidea Biopharmaceuticals reported fiscal year 2020 executive compensation information on August 2, 2021.
In 2020, three executives at Navidea Biopharmaceuticals received on average a compensation package of $618K, a 46% increase compared to previous year.
Average pay of disclosed executives at Navidea Biopharmaceuticals
Jed A. Latkin, Chief Executive Officer, received $1.2M in total, which increased by 66% compared to 2019. 39% of Latkin's compensation, or $482K, was in salary. Latkin also received $253K in non-equity incentive plan, $322K in option awards, $163K in stock awards, as well as $5.7K in other compensation.
Joel H. Kaufman, Chief Business Officer, received a compensation package of $326K, which increased by 19% compared to previous year. 69% of the compensation package, or $226K, was in salary.
Michael S. Rosol, Chief Medical Officer, earned $302K in 2020, a 21% increase compared to previous year.

Related executives

Jed Latkin

Navidea Biopharmaceuticals

Chief Executive Officer

Joel Kaufman

Navidea Biopharmaceuticals

Chief Business Officer

Michael Rosol

Navidea Biopharmaceuticals

Chief Medical Officer

You may also like

Source: SEC filing on August 2, 2021.